DOCSLIB.ORG

Free PDF Download

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Free PDF Download European Review for Medical and Pharmacological Sciences 2021; 25: 1622-1630 Superantigens, superantigen-like proteins and superantigen derivatives for cancer treatment J.-Y. CHEN Xiehe Biology Group, Nobel Institute of Medicine, Shenzhen, Guangdong Province, China Abstract. – OBJECTIVE: Bacterial superanti- gesting a more complex mechanism of immune gens (SAgs) are proteins produced by few types response6. Indeed, the current view is that SAgs of bacteria that have been linked to several hu- bind to multiple coreceptors forming a costimu- man diseases. Due to their potent in vitro and in latory axis between coreceptors critical for T-cell vivo tumoricidal effects, they are extensively in- 7 vestigated for oncological applications either activation . CD28 is a homodimer expressed alone or in combination with classical antican- constitutively on T cells that interacts with its cer drugs. However, the intrinsic toxicity of nat- B7 coligands expressed on antigen-presenting ural SAgs stimulated the development of more cells, transducing the signal essential for T cell effective and less toxic SAg-based immunother- activation. The staphylococcal superantigen-like apy. This review summarizes our current knowl- protein 1 (SSL1) specifically binds to human edge on SAg-based immunotherapy including extracellular signal-regulated kinase 2 (hERK2), SAg-like proteins and SAg derivatives, as well as their potential alone or with other therapeu- an important stress-activated kinase in mito- 8 tic modalities including chemotherapy and ra- gen-activated protein kinase signaling pathways . diotherapy. It is now clearer that SAgs induce the release of cytokines and chemokines through multiple Key Words: pathways as it was recently observed in in vitro Superantigen, Superantigen derivative, Superanti- 9 gen-like, Cancer, Combination therapy experiments . SAgs can cause severe poisoning and several serious human diseases. For instance, Staphylo- coccus aureus enterotoxins have potent super- Introduction antigenic activity associated with frequent food poisoning outbreaks10, toxic shock syndrome11,12, Bacterial Superantigens (SAgs), also common- pneumonia13, Kawasaki disease14-17, nasopha- ly known as erythrogenic toxins or streptococcal ryngeal infections18, atopic dermatitis (AD), and pyrogenic exotoxins1, are the most potent types chronic rhinosinusitis (CRS) and sepsis-related of T cell mitogens. SAgs are produced by only a infections. few bacterial pathogens, including Staphylococ- SAgs can induce the production of cytokines cus aureus2. The majority are produced by the leading to the hypothesis that viral proteins with Gram-positive organisms Staphylococcus aureus a possible superantigen activity may be responsi- and Streptococcus pyogenes3,4. Bacterial SAgs at ble for the systemic shock, acute respiratory syn- a very low concentration (typically < 0.1 pg/ml) drome, multiorgan failure and consequently death are sufficient to stimulate the T lymphocytes5. In observed in patients with COVID-1919. A recent vitro femtomolar concentrations of SAgs are able finding from in silico studies suggests that small to stimulate profound proliferation and cytokine insertions unique to SARS-CoV-2 (SARS-CoV-2 production in up to 20% of all peripheral T cells6. Spike) can display SAg activity and support this It was initially thought that the powerful immune hypothesis20. It is relatively well established that response generated by SAgs was due to its bind- at least one of the mechanisms by which SAgs ing to Major Histocompatibility Complex class II contribute to systemic multiorgan failure is the molecules on antigen-presenting cells and T cell production of a cytokine storm by enhancing receptors on T cells. Later, it was found that the the B7-2/CD28 costimulatory receptor interac- staphylococcal enterotoxin B (SEB) SAg, also tion21,22. The formation of the B7-2/CD28 costim- binds the co-stimulatory molecule CD28 sug- ulatory axis is critical for full T-cell activation21. 1622 Corresponding Author: Juyu Chen, MD; e-mail: [email protected] Superantigens, superantigen-like proteins and superantigen derivatives for cancer treatment Picomolar amounts of staphylococcal entero- at very low dosage but of limited use due to toxin A (SEA) SAg rapidly induced cytotoxic ac- toxic effects27. Natural superantigens have been tivity against K562 and Raji cells, as well as some used for cancer immunotherapy but at the cost of natural-killer (NK)-resistant tumour cell lines23 severe side effects due to their ability to induce which could be of value in therapeutic applica- high systemic levels of a large panel of inflam- tions. Therefore, despite the serious toxic and matory cytokines that may lead to a toxic shock adverse effects, SAgs are actively investigated as syndrome and therefore attempts to translate the therapeutic tools for cancer treatment. The aim of in vitro antitumor effect into clinical trials have this article is to provide a concise review of the been limited. To increase the effect of the SAgs, potential application of SAgs, SAg-like proteins the concept of tumor-targeted SAgs (TTS) was and SAg derivatives for cancer treatment. established with the aim of recruiting a large number of T cells (Figure 1). In addition, be- SAgs for Cancer Treatment cause of the differential species susceptibilities, For their ability to potentially activate T lym- predicting the toxicity of SAgs in humans is phocytes, SAgs have been used clinically as difficult. For instance, mice are not valid human an immunomodifier in the treatment of tumors. disease models because they are significantly The SAg Staphylococcal enterotoxin A (SEA) less sensitive to toxic shock induced by bacterial when co-cultured with human peripheral blood SAgs when compared with primates and rab- mononuclear cells (PBMCs) inhibited the pro- bits28. These limitations triggered the evaluation liferation and induced the death of human lung of other SAg alternatives such as SAg-like pro- carcinoma A549 cells24. The Staphylococcal en- teins and derivatives. terotoxin B (SEB) is an efficient activator of the antitumor immune response that leads to the SAg-Like Proteins eradication of tumor growth and inhibition of The common structure and function of the metastasis25. SEB-Superantigen-activated PBMC SAgs are also shared by another group of staph- (peripheral blood mononuclear cells) significantly ylococcal virulence factors called the superanti- induced apoptosis in transitional cell carcinoma gen-like proteins (SAg-like proteins)4. Staphylo- cells (TCC)26. The Staphylococcal enterotoxin coccal enterotoxin-like toxins (SEls) are proteins C2 (SEC2) is another classical SAg with potent with similar amino acid sequences to those of antitumor activity by activating T lymphocytes classical SAgs but they exhibit low or no emetic Figure 1. Potential immunotherapy using Tumor-Targeted Superantigen (SAg) (Modified from61). A SAg or SAg-based ligand can be linked to a tumor-specific antibody or ligand. The tumor-specific antibody/ligand binds to the tumor antigen whereas the superantigen/ligand crosslink between the major histocompatibility complex class II molecule (MHC-II) and the T cell receptor (TCR) induces T-cell hyperactivation of a T lymphocyte (shown in this figure) and monocytes/macrophages and results in the release of huge amounts of cytokines and chemokines, such as tumor necrosis factor α (TNF-α), interleukin 1 (IL-1), IL-2, interferon γ (IFN-γ). and many others. This leads to T-cell dependent tumor killing likely by apoptosis. APC = Antigen Presenting cell. 1623 J.-Y. Chen Figure 2. Potential mechanism of action of ABR-217620 (Naptumomab estafenatox; 5T4Fab-SEA/E-120). Modified from55. T lymphocyte activation occurs through its T-cell receptor (TCR) upon binding of the fusion protein ABR-217620 to the 5T4 tumor-associated antigen. The T cell kills tumoral cells directly by its cytotoxic T lymphocyte (CTL) activity and indirectly by producing cytokines (tumor necrosis factor [TNFa] – and interferon [IFNg ). activity and have anticancer effects by activat- SAg Derivatives ing lymphocytes particularly CD4+ and CD8+ T SAg derivatives have been created to reduce cells29. Treatment with a low concentration of systemic toxicity while maintaining profound an- Staphylococcal enterotoxin-like Q (SElQ) (30 µg/ titumor effects. SAg side-effects may be caused mouse) could inhibit the growth of tumors by by nonspecific binding to class II positive cells. approximately 30% without significant toxicity29. To overcome this, several authors created mutat- Staphylococcal SAg-like protein 6 (SSL6) inhibit- ed staphylococcal enterotoxin A (SEA). In partic- ed CD47 and promoted Sorafenib-induced apop- ular, Hansson et al35 created a tumor-reactive SAg tosis of hepatocellular carcinoma cells Huh-7 and by engineering a fusion protein composed of a MHCC97H30 that are widely used as liver cancer tumor-reactive mAb (C215Fab) and the bacterial models. Other staphylococcal SAg-like protein SAg staphylococcal enterotoxin A (SEA) (SEA), such as staphylococcal SAg-like protein 7 (SSL7) a well-known SAg. They introduced a point mu- have been shown to inhibit the formation of the tation (D227A) at the major MHC class II binding complement membrane attack complex (MAC) site. The Fab–SEA D227A fusion protein showed and can be useful for treating complement-me- profound antitumor effects with a markedly re- diated hemolysis31. Recombinant staphylococcus duced toxicity as compared with the wild-type aureus SAg-like protein 7 -that inhibits
Load more

Recommended publications
  • The Role of Streptococcal and Staphylococcal Exotoxins and Proteases in Human Necrotizing Soft Tissue Infections
    toxins Review The Role of Streptococcal and Staphylococcal Exotoxins and Proteases in Human Necrotizing Soft Tissue Infections Patience Shumba 1, Srikanth Mairpady Shambat 2 and Nikolai Siemens 1,* 1 Center for Functional Genomics of Microbes, Department of Molecular Genetics and Infection Biology, University of Greifswald, D-17489 Greifswald, Germany; [email protected] 2 Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, CH-8091 Zurich, Switzerland; [email protected] * Correspondence: [email protected]; Tel.: +49-3834-420-5711 Received: 20 May 2019; Accepted: 10 June 2019; Published: 11 June 2019 Abstract: Necrotizing soft tissue infections (NSTIs) are critical clinical conditions characterized by extensive necrosis of any layer of the soft tissue and systemic toxicity. Group A streptococci (GAS) and Staphylococcus aureus are two major pathogens associated with monomicrobial NSTIs. In the tissue environment, both Gram-positive bacteria secrete a variety of molecules, including pore-forming exotoxins, superantigens, and proteases with cytolytic and immunomodulatory functions. The present review summarizes the current knowledge about streptococcal and staphylococcal toxins in NSTIs with a special focus on their contribution to disease progression, tissue pathology, and immune evasion strategies. Keywords: Streptococcus pyogenes; group A streptococcus; Staphylococcus aureus; skin infections; necrotizing soft tissue infections; pore-forming toxins; superantigens; immunomodulatory proteases; immune responses Key Contribution: Group A streptococcal and Staphylococcus aureus toxins manipulate host physiological and immunological responses to promote disease severity and progression. 1. Introduction Necrotizing soft tissue infections (NSTIs) are rare and represent a more severe rapidly progressing form of soft tissue infections that account for significant morbidity and mortality [1].
    [Show full text]
  • The Role of Epidermal Growth Factor Receptor in Cancer and Their Application Oncology Section for New Targeted Cancer Therapy
    DOI: 10.7860/JCDR/2018/35499.11680 Review Article The Role of Epidermal Growth Factor Receptor in Cancer and their Application Oncology Section for New Targeted Cancer Therapy FARAJOLAH MALEKI1, SADEGHIFARD NOORKHODA2, RAHELEH HALABIAN3, ELHAM BEHZADI4, ABBAS ALI IMANI FOOLADI5 ABSTRACT Epidermal Growth Factor Receptor (EGFR) has central role in cancer therapy because it causes tumour progression in many cases. The EGFR has seven ligands. Each factor that can block this binding, inhibits the intracellular signal transduction and prevents progression of the tumours. Immune system response is the most important factor for suppressing the initial stage of tumour growth and destroying some initial malignant cells, daily. On the other hand, tumours have different mechanisms to hide their antigens and escape from immune system responses. In contrary, tumours use some mechanisms to escape from immune system such as: 1) use of TGF-β to initiate angiogenesis and immune suppression; 2) Induces Treg cell activation to modulate other immune cells; 3) secretion of the prostaglandin E2 to convert T cell into Treg. So, if a superantigen fused to one of the EGFR-ligands, causes the induction of immune system responses against the tumour cells. One of the new methods is based on the use of the fused super antigen with a ligand of the EGFR to inhibit ligand attaching to the EGFR and inducing immune system responses. To achieve this goal, we can block binding of EGFR to their ligands in the extracellular domain by fusing ligands with bacterial superantigens, toxins or cytokines of the viruses and plants that can induce immune system responses and kill malignant cells.
    [Show full text]
  • Biological Toxins As the Potential Tools for Bioterrorism
    International Journal of Molecular Sciences Review Biological Toxins as the Potential Tools for Bioterrorism Edyta Janik 1, Michal Ceremuga 2, Joanna Saluk-Bijak 1 and Michal Bijak 1,* 1 Department of General Biochemistry, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland; [email protected] (E.J.); [email protected] (J.S.-B.) 2 CBRN Reconnaissance and Decontamination Department, Military Institute of Chemistry and Radiometry, Antoniego Chrusciela “Montera” 105, 00-910 Warsaw, Poland; [email protected] * Correspondence: [email protected] or [email protected]; Tel.: +48-(0)426354336 Received: 3 February 2019; Accepted: 3 March 2019; Published: 8 March 2019 Abstract: Biological toxins are a heterogeneous group produced by living organisms. One dictionary defines them as “Chemicals produced by living organisms that have toxic properties for another organism”. Toxins are very attractive to terrorists for use in acts of bioterrorism. The first reason is that many biological toxins can be obtained very easily. Simple bacterial culturing systems and extraction equipment dedicated to plant toxins are cheap and easily available, and can even be constructed at home. Many toxins affect the nervous systems of mammals by interfering with the transmission of nerve impulses, which gives them their high potential in bioterrorist attacks. Others are responsible for blockage of main cellular metabolism, causing cellular death. Moreover, most toxins act very quickly and are lethal in low doses (LD50 < 25 mg/kg), which are very often lower than chemical warfare agents. For these reasons we decided to prepare this review paper which main aim is to present the high potential of biological toxins as factors of bioterrorism describing the general characteristics, mechanisms of action and treatment of most potent biological toxins.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix
    United States International Trade Commission Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix USITC Publication 4208 December 2010 U.S. International Trade Commission COMMISSIONERS Deanna Tanner Okun, Chairman Irving A. Williamson, Vice Chairman Charlotte R. Lane Daniel R. Pearson Shara L. Aranoff Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix Publication 4208 December 2010 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 15, 2010, set forth at the end of this publication, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the United States International Trade Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement changes to the Pharmaceutical Appendix, effective on January 1, 2011. Table 1 International Nonproprietary Name (INN) products proposed for addition to the Pharmaceutical Appendix to the Harmonized Tariff Schedule INN CAS Number Abagovomab 792921-10-9 Aclidinium Bromide 320345-99-1 Aderbasib 791828-58-5 Adipiplon 840486-93-3 Adoprazine 222551-17-9 Afimoxifene 68392-35-8 Aflibercept 862111-32-8 Agatolimod
    [Show full text]
  • Medical Management of Biologic Casualties Handbook
    USAMRIID’s MEDICAL MANAGEMENT OF BIOLOGICAL CASUALTIES HANDBOOK Fourth Edition February 2001 U.S. ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES ¨ FORT DETRICK FREDERICK, MARYLAND 1 Sources of information: National Response Center 1-800-424-8802 or (for chem/bio hazards & terrorist events) 1-202-267-2675 National Domestic Preparedness Office: 1-202-324-9025 (for civilian use) Domestic Preparedness Chem/Bio Help line: 1-410-436-4484 or (Edgewood Ops Center - for military use) DSN 584-4484 USAMRIID Emergency Response Line: 1-888-872-7443 CDC'S Bioterrorism Preparedness and Response Center: 1-770-488-7100 John's Hopkins Center for Civilian Biodefense: 1-410-223-1667 (Civilian Biodefense Studies) An Adobe Acrobat Reader (pdf file) version and a Palm OS Electronic version of this Handbook can both be downloaded from the Internet at: http://www.usamriid.army.mil/education/bluebook.html 2 USAMRIID’s MEDICAL MANAGEMENT OF BIOLOGICAL CASUALTIES HANDBOOK Fourth Edition February 2001 Editors: LTC Mark Kortepeter LTC George Christopher COL Ted Cieslak CDR Randall Culpepper CDR Robert Darling MAJ Julie Pavlin LTC John Rowe COL Kelly McKee, Jr. COL Edward Eitzen, Jr. Comments and suggestions are appreciated and should be addressed to: Operational Medicine Department Attn: MCMR-UIM-O U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) Fort Detrick, Maryland 21702-5011 3 PREFACE TO THE FOURTH EDITION The Medical Management of Biological Casualties Handbook, which has become affectionately known as the "Blue Book," has been enormously successful - far beyond our expectations. Since the first edition in 1993, the awareness of biological weapons in the United States has increased dramatically.
    [Show full text]
  • SARS-Cov-2 As a Superantigen in Multisystem Inflammatory Syndrome in Children (MIS-C)
    SARS-CoV-2 as a superantigen in multisystem inflammatory syndrome in children (MIS-C) Theodore Kouo, Worarat Chaisawangwong J Clin Invest. 2021. https://doi.org/10.1172/JCI149327. Commentary In-Press Preview Multisystem Inflammatory Syndrome in Children (MIS-C) is a rare but deadly new disease in children that rapidly progresses to hyperinflammation, shock, and can lead to multiple organ failure if unrecognized. It has been found to be temporally associated with the COVID-19 pandemic and is often associated with SARS-CoV-2 exposure in children. In this issue of the JCI, Porritt, Paschold, and Rivas et al. identify restricted T cell receptor (TCR) β-chain variable domain (Vβ) usage in patients with severe MIS-C indicating a potential role for SARS-CoV-2 as a superantigen. These findings suggest that a blood test that determines the presence of specific TCR beta variable gene segments (TRBV) may identify patients at risk for severe MIS-C. Find the latest version: https://jci.me/149327/pdf SARS-CoV-2 as a superantigen in multisystem inflammatory syndrome in children (MIS-C) Theodore Kouo1 and Worarat Chaisawangwong2 1Department of Pediatrics, Division of Emergency Medicine, 2Department of Pathology, Johns Hopkins University, School of Medicine, Baltimore, MD, USA. Address correspondence to: Theodore Kouo Johns Hopkins Children’s Center 1800 Orleans Street, G1509 Phone: 410-955-6146 Email: [email protected] COI Statement: The authors declare that no conflict of interest exists. Abstract Multisystem Inflammatory Syndrome in Children (MIS-C) is a rare but deadly new disease in children that rapidly progresses to hyperinflammation, shock, and can lead to multiple organ failure if unrecognized.
    [Show full text]
  • Medical Management of Biological Casualties Handbook
    USAMRIID’s MEDICAL MANAGEMENT OF BIOLOGICAL CASUALTIES HANDBOOK Sixth Edition April 2005 U.S. ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES FORT DETRICK FREDERICK, MARYLAND Emergency Response Numbers National Response Center: 1-800-424-8802 or (for chem/bio hazards & terrorist events) 1-202-267-2675 National Domestic Preparedness Office: 1-202-324-9025 (for civilian use) Domestic Preparedness Chem/Bio Helpline: 1-410-436-4484 or (Edgewood Ops Center – for military use) DSN 584-4484 USAMRIID’s Emergency Response Line: 1-888-872-7443 CDC'S Emergency Response Line: 1-770-488-7100 Handbook Download Site An Adobe Acrobat Reader (pdf file) version of this handbook can be downloaded from the internet at the following url: http://www.usamriid.army.mil USAMRIID’s MEDICAL MANAGEMENT OF BIOLOGICAL CASUALTIES HANDBOOK Sixth Edition April 2005 Lead Editor Lt Col Jon B. Woods, MC, USAF Contributing Editors CAPT Robert G. Darling, MC, USN LTC Zygmunt F. Dembek, MS, USAR Lt Col Bridget K. Carr, MSC, USAF COL Ted J. Cieslak, MC, USA LCDR James V. Lawler, MC, USN MAJ Anthony C. Littrell, MC, USA LTC Mark G. Kortepeter, MC, USA LTC Nelson W. Rebert, MS, USA LTC Scott A. Stanek, MC, USA COL James W. Martin, MC, USA Comments and suggestions are appreciated and should be addressed to: Operational Medicine Department Attn: MCMR-UIM-O U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) Fort Detrick, Maryland 21702-5011 PREFACE TO THE SIXTH EDITION The Medical Management of Biological Casualties Handbook, which has become affectionately known as the "Blue Book," has been enormously successful - far beyond our expectations.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • Penetration of Stratified Mucosa Cytolysins Augment Superantigen
    Cytolysins Augment Superantigen Penetration of Stratified Mucosa Amanda J. Brosnahan, Mary J. Mantz, Christopher A. Squier, Marnie L. Peterson and Patrick M. Schlievert This information is current as of September 25, 2021. J Immunol 2009; 182:2364-2373; ; doi: 10.4049/jimmunol.0803283 http://www.jimmunol.org/content/182/4/2364 Downloaded from References This article cites 76 articles, 24 of which you can access for free at: http://www.jimmunol.org/content/182/4/2364.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 25, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2009 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Cytolysins Augment Superantigen Penetration of Stratified Mucosa1 Amanda J. Brosnahan,* Mary J. Mantz,† Christopher A. Squier,† Marnie L. Peterson,‡ and Patrick M. Schlievert2* Staphylococcus aureus and Streptococcus pyogenes colonize mucosal surfaces of the human body to cause disease. A group of virulence factors known as superantigens are produced by both of these organisms that allows them to cause serious diseases from the vaginal (staphylococci) or oral mucosa (streptococci) of the body.
    [Show full text]
  • Nasopharyngeal Infection by Streptococcus Pyogenes Requires Superantigen-Responsive Vβ-Specific T Cells
    Nasopharyngeal infection by Streptococcus pyogenes requires superantigen-responsive Vβ-specific T cells Joseph J. Zeppaa, Katherine J. Kaspera, Ivor Mohorovica, Delfina M. Mazzucaa, S. M. Mansour Haeryfara,b,c,d, and John K. McCormicka,c,d,1 aDepartment of Microbiology and Immunology, Schulich School of Medicine & Dentistry, Western University, London, ON N6A 5C1, Canada; bDepartment of Medicine, Division of Clinical Immunology & Allergy, Schulich School of Medicine & Dentistry, Western University, London, ON N6A 5A5, Canada; cCentre for Human Immunology, Western University, London, ON N6A 5C1, Canada; and dLawson Health Research Institute, London, ON N6C 2R5, Canada Edited by Philippa Marrack, Howard Hughes Medical Institute, National Jewish Health, Denver, CO, and approved July 14, 2017 (received for review January 18, 2017) The globally prominent pathogen Streptococcus pyogenes secretes context of invasive streptococcal disease is extremely dangerous, potent immunomodulatory proteins known as superantigens with a mortality rate of over 30% (10). (SAgs), which engage lateral surfaces of major histocompatibility The role of SAgs in severe human infections has been well class II molecules and T-cell receptor (TCR) β-chain variable domains established (5, 11, 12), and specific MHC-II haplotypes are known (Vβs). These interactions result in the activation of numerous Vβ- risk factors for the development of invasive streptococcal disease specific T cells, which is the defining activity of a SAg. Although (13), an outcome that has been directly linked to SAgs (14, 15). streptococcal SAgs are known virulence factors in scarlet fever However, how these exotoxins contribute to superficial disease and and toxic shock syndrome, mechanisms by how SAgs contribute colonization is less clear.
    [Show full text]
  • Production of Superantigens in Staphylococcus Aureus From
    Superantigen and Toxin Information Production of ● Staphylococcal Enterotoxins (SEs) ○ Category B select agents ○ Resistant to heat and acid Superantigens in ○ Express emetic activity ■ Throwing up ● Staphylococcal Enterotoxin A (SEA) Staphylococcus ○ Most common in staph related food poisoning ● Staphylococcal Enterotoxin C 4 (SEC4) ○ Seen in non-menstrual Toxic Shock Syndrome aureus from healthy (TSS) ○ Produced mainly by pathogenic or MRSA strains ● Toxic Shock Syndrome Toxin-1 (TSST-1) individuals ○ Cause of menstrual TSS and half of non-menstrual TSS Skye Martin, Dr. Mandy Staphylococcus aureus isolated from ○ Has the ability to cross mucosal barriers ● Alpha Brosnahan and Dr. Taylor Mach ○ Pore-forming toxin (only one that isn’t a superantigen on our list) Background: anterior nares of healthy individuals typically ■ Causes cell lysis, specifically hemolysis ● The study has collected nasal swabs from healthy ○ Associated with pulmonary edema (excess of fluid individuals on Concordia St. Paul Campus (CSP) and in lungs) at the Minnesota State fair (D2D) don’t have the TSST-1 toxin but have alpha ● Staphylococcal Enterotoxin-like X (SEl-X) ● Staphylococcus aureus is a commensal and ○ Only SE to attack the innate (neutrophils) and opportunistic bacteria adaptive (T-cells) immune system ● Those swabs are tested to determine if they are S. ○ Associated with toxic shock syndrome and aureus and SEl-X toxins. necrotizing pneumonia Alpha toxin run 1 gel image: ● Positive isolates are then tested for 5 toxins (SEA, SEC4, TSST-1, Alpha and SEl-X ● s0### = isolate labeling ● Bands at the same base pair as the positive control is a positive result ● No bands or bands at different base pairs as the positive control is a negative result ● Total of 139 isolates tested since Fall 2019 Acknowledgements: Methods: Special thanks to Dr.
    [Show full text]
  • Botulinum Toxin Ricin Toxin Staph Enterotoxin B
    Botulinum Toxin Ricin Toxin Staph Enterotoxin B Source Source Source Clostridium botulinum, a large gram- Ricinus communis . seeds commonly called .Staphylococcus aureus, a gram-positive cocci positive, spore-forming, anaerobic castor beans bacillus Characteristics Characteristics .Appears as grape-like clusters on Characteristics .Toxin can be disseminated in the form of a Gram stain or as small off-white colonies .Grows anaerobically on Blood Agar and liquid, powder or mist on Blood Agar egg yolk plates .Toxin-producing and non-toxigenic strains Pathogenesis of S. aureus will appear morphologically Pathogenesis .A-chain inactivates ribosomes, identical interrupting protein synthesis .Toxin enters nerve terminals and blocks Pathogenesis release of acetylcholine, blocking .B-chain binds to carbohydrate receptors .Staphylococcus Enterotoxin B (SEB) is a neuro-transmission and resulting in on the cell surface and allows toxin superantigen. Toxin binds to human class muscle paralysis complex to enter cell II MHC molecules causing cytokine Toxicity release and system-wide inflammation Toxicity .Highly toxic by inhalation, ingestion Toxicity .Most lethal of all toxic natural substances and injection .Toxic by inhalation or ingestion .Groups A, B, E (rarely F) cause illness in .Less toxic by ingestion due to digestive humans activity and poor absorption Symptoms .Low dermal toxicity .4-10 h post-ingestion, 3-12 h post-inhalation Symptoms .Flu-like symptoms, fever, chills, .24-36 h (up to 3 d for wound botulism) Symptoms headache, myalgia .Progressive skeletal muscle weakness .18-24 h post exposure .Nausea, vomiting, and diarrhea .Symmetrical descending flaccid paralysis .Fever, cough, chest tightness, dyspnea, .Nonproductive cough, chest pain, .Can be confused with stroke, Guillain- cyanosis, gastroenteritis and necrosis; and dyspnea Barre syndrome or myasthenia gravis death in ~72 h .SEB can cause toxic shock syndrome + + + Gram stain Lipase on Ricin plant Castor beans S.
    [Show full text]